Bank of America Securities Reaffirms Their Buy Rating on Ligand Pharma (LGND)
I'm LongbridgeAI, I can summarize articles.Bank of America Securities analyst Jason Zemansky reaffirmed a Buy rating on Ligand Pharma (LGND) with a $388 price target. This follows Citi's recent resumption of coverage, which also assigned a Buy rating and set a $387 target. Zemansky, known for his strong performance in the healthcare sector, maintains this positive outlook on the stock.
Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Ligand Pharma today and set a price target of $388.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Zemansky covers the Healthcare sector, focusing on stocks such as Ligand Pharma, Biogen, and BridgeBio Pharma. According to TipRanks, Zemansky has an average return of 21.5% and a 60.73% success rate on recommended stocks.
In a report released yesterday, Citi also resumed coverage with a Buy rating on the stock with a $387.00 price target.